JP2023539344A - カボテグラビルおよびレボノルゲストレルの組合せ - Google Patents

カボテグラビルおよびレボノルゲストレルの組合せ Download PDF

Info

Publication number
JP2023539344A
JP2023539344A JP2023514081A JP2023514081A JP2023539344A JP 2023539344 A JP2023539344 A JP 2023539344A JP 2023514081 A JP2023514081 A JP 2023514081A JP 2023514081 A JP2023514081 A JP 2023514081A JP 2023539344 A JP2023539344 A JP 2023539344A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
contraceptive
levonorgestrel
combination
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539344A5 (https=
JPWO2022051198A5 (https=
Inventor
ニマ、アハベイン
シモーネ、アリドリ
エミール、ヨハン、フェルトハイゼン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Publication of JP2023539344A publication Critical patent/JP2023539344A/ja
Publication of JP2023539344A5 publication Critical patent/JP2023539344A5/ja
Publication of JPWO2022051198A5 publication Critical patent/JPWO2022051198A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023514081A 2020-09-01 2021-08-30 カボテグラビルおよびレボノルゲストレルの組合せ Pending JP2023539344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073140P 2020-09-01 2020-09-01
US63/073,140 2020-09-01
PCT/US2021/048127 WO2022051198A1 (en) 2020-09-01 2021-08-30 Combination of cabotegravir and levonorgestrel

Publications (3)

Publication Number Publication Date
JP2023539344A true JP2023539344A (ja) 2023-09-13
JP2023539344A5 JP2023539344A5 (https=) 2024-09-06
JPWO2022051198A5 JPWO2022051198A5 (https=) 2024-09-06

Family

ID=77897768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514081A Pending JP2023539344A (ja) 2020-09-01 2021-08-30 カボテグラビルおよびレボノルゲストレルの組合せ

Country Status (4)

Country Link
US (1) US20230321089A1 (https=)
EP (1) EP4208169A1 (https=)
JP (1) JP2023539344A (https=)
WO (1) WO2022051198A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068743A1 (en) * 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
CN121909019A (zh) * 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500849A (ja) * 2010-09-16 2014-01-16 ヴィーブ ヘルスケア カンパニー 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500849A (ja) * 2010-09-16 2014-01-16 ヴィーブ ヘルスケア カンパニー 医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"HORMONAL CONTRACEPTIVES DO NOT ALTER CABOTEGRAVIR PK IN HIV UNINFECTED WOMEN: HPTN 077", JPN6025037449, 2019, ISSN: 0005807621 *
"NEXT GENERATION OF TRANSLATIONAL LONG-ACTING CABOTEGRAVIR", JPN6025037450, 2018, ISSN: 0005807622 *
BJCP, vol. 83, JPN6025037448, 2017, pages 1499 - 1505, ISSN: 0005807620 *
CONTRACEPTION, vol. 95, no. 1, JPN6025037452, 2017, pages 55 - 58, ISSN: 0005807624 *
PHARM RES, vol. 32, JPN6025037451, 2015, pages 2180 - 2191, ISSN: 0005807623 *

Also Published As

Publication number Publication date
US20230321089A1 (en) 2023-10-12
EP4208169A1 (en) 2023-07-12
WO2022051198A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
JP7703538B2 (ja) カボテグラビルを含んでなる医薬組成物
US12138264B2 (en) Pharmaceutical compositions
JP7232128B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2017132791A (ja) 組み合わせ組成物
JP2023539344A (ja) カボテグラビルおよびレボノルゲストレルの組合せ
CN106999425A (zh) 长效药物组合物
JP2025020306A (ja) アリピプラゾール注射用調製物を投与する方法
US20150209273A1 (en) Pharmaceutical Compositions
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
Fica et al. Penicillin desensitization in allergic pregnant women with syphilis in a developing country. Report of two cases.
JP2020527570A (ja) 組み合わせ薬物療法
TW202227088A (zh) 組合療法
JP2009509993A (ja) ヘルペス性角膜炎の治療のためのブリブジンを含む光安定性医薬品成物
AU2019365204B2 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations
TW202602442A (zh) 給藥方案
TW202320788A (zh) 用於治療或預防抗宿主病的吡咯并六元雜芳物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303